Published in Sci Transl Med on April 04, 2012
Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev (2013) 3.44
Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat Nanotechnol (2013) 3.39
Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev (2012) 3.34
Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res (2013) 2.98
Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat Rev Drug Discov (2014) 2.20
Can exercise teach us how to treat heart disease? Circulation (2012) 1.70
Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. J Control Release (2013) 1.64
Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery. Nano Lett (2014) 1.55
P-selectin is a nanotherapeutic delivery target in the tumor microenvironment. Sci Transl Med (2016) 1.52
PET imaging in prostate cancer: focus on prostate-specific membrane antigen. Curr Top Med Chem (2013) 1.42
Managing diabetes with nanomedicine: challenges and opportunities. Nat Rev Drug Discov (2014) 1.39
Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo. ACS Nano (2013) 1.39
Microfluidic technologies for accelerating the clinical translation of nanoparticles. Nat Nanotechnol (2012) 1.39
Transepithelial transport of Fc-targeted nanoparticles by the neonatal fc receptor for oral delivery. Sci Transl Med (2013) 1.38
A holistic approach to targeting disease with polymeric nanoparticles. Nat Rev Drug Discov (2015) 1.31
Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug. Proc Natl Acad Sci U S A (2013) 1.30
Development and in vivo efficacy of targeted polymeric inflammation-resolving nanoparticles. Proc Natl Acad Sci U S A (2013) 1.27
Engineering of blended nanoparticle platform for delivery of mitochondria-acting therapeutics. Proc Natl Acad Sci U S A (2012) 1.27
Polymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugs. Int J Pharm (2012) 1.25
Targeted therapy using nanotechnology: focus on cancer. Int J Nanomedicine (2014) 1.22
Recent progress in nanomedicine: therapeutic, diagnostic and theranostic applications. Curr Opin Biotechnol (2013) 1.19
Nanotechnology: Carrying drugs. Nature (2012) 1.19
Interactions of nanomaterials and biological systems: Implications to personalized nanomedicine. Adv Drug Deliv Rev (2012) 1.18
Engineered nanomedicine for myeloma and bone microenvironment targeting. Proc Natl Acad Sci U S A (2014) 1.16
Cancer nanomedicine: from targeted delivery to combination therapy. Trends Mol Med (2015) 1.13
The role of philosophy of science in Responsible Research and Innovation (RRI): the case of nanomedicine. Life Sci Soc Policy (2014) 1.12
Challenges associated with Penetration of Nanoparticles across Cell and Tissue Barriers: A Review of Current Status and Future Prospects. Nano Today (2014) 1.09
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev (2015) 1.08
Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle. Proc Natl Acad Sci U S A (2013) 1.08
Insight into nanoparticle cellular uptake and intracellular targeting. J Control Release (2014) 1.08
Future Perspectives of Radionanomedicine Using the Novel Micelle-Encapsulation Method for Surface Modification. Nucl Med Mol Imaging (2015) 1.06
DNA self-assembly of targeted near-infrared-responsive gold nanoparticles for cancer thermo-chemotherapy. Angew Chem Int Ed Engl (2012) 1.05
Proof of concept for next-generation nanoparticle drugs in humans. Nat Biotechnol (2012) 1.04
Nanoparticle drug loading as a design parameter to improve docetaxel pharmacokinetics and efficacy. Biomaterials (2013) 1.04
Translating materials design to the clinic. Nat Mater (2013) 1.03
Delivering nanoparticles to lungs while avoiding liver and spleen through adsorption on red blood cells. ACS Nano (2013) 1.02
Polymeric nanoparticles for targeted treatment in oncology: current insights. Int J Nanomedicine (2015) 1.00
Nanoparticles for combination drug therapy. ACS Nano (2013) 0.99
Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer (2016) 0.99
Canonical and non-canonical barriers facing antimiR cancer therapeutics. Curr Med Chem (2013) 0.98
Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticles. Nanomedicine (Lond) (2012) 0.97
Prostate-specific membrane antigen as a target for cancer imaging and therapy. Q J Nucl Med Mol Imaging (2015) 0.97
Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug. Nat Commun (2015) 0.97
Design considerations for nanotherapeutics in oncology. Nanomedicine (2015) 0.96
Microfluidic platform for combinatorial synthesis and optimization of targeted nanoparticles for cancer therapy. ACS Nano (2013) 0.96
Cancer active targeting by nanoparticles: a comprehensive review of literature. J Cancer Res Clin Oncol (2014) 0.96
Environment-responsive nanophores for therapy and treatment monitoring via molecular MRI quenching. Nat Commun (2014) 0.95
Polydopamine-based simple and versatile surface modification of polymeric nano drug carriers. ACS Nano (2014) 0.95
⁶⁴Cu-labeled inhibitors of prostate-specific membrane antigen for PET imaging of prostate cancer. J Med Chem (2014) 0.94
Synthesis of polymer-lipid nanoparticles for image-guided delivery of dual modality therapy. Bioconjug Chem (2013) 0.94
Nanoparticles for imaging, sensing, and therapeutic intervention. ACS Nano (2014) 0.94
Anti-cancer activity of curcumin loaded nanoparticles in prostate cancer. Biomaterials (2014) 0.94
Prediction of nanoparticle prodrug metabolism by pharmacokinetic modeling of biliary excretion. J Control Release (2013) 0.93
Particle replication in nonwetting templates nanoparticles with tumor selective alkyl silyl ether docetaxel prodrug reduces toxicity. Nano Lett (2014) 0.93
Clinical Translation of Nanomedicine. Chem Rev (2015) 0.93
Nanoways to overcome docetaxel resistance in prostate cancer. Drug Resist Updat (2014) 0.92
Ultra-high throughput synthesis of nanoparticles with homogeneous size distribution using a coaxial turbulent jet mixer. ACS Nano (2014) 0.92
Polymeric nanoparticle technologies for oral drug delivery. Clin Gastroenterol Hepatol (2014) 0.92
Nanoparticles that deliver triplex-forming peptide nucleic acid molecules correct F508del CFTR in airway epithelium. Nat Commun (2015) 0.91
Parallel microfluidic synthesis of size-tunable polymeric nanoparticles using 3D flow focusing towards in vivo study. Nanomedicine (2013) 0.90
Polymer nanoparticles for drug and small silencing RNA delivery to treat cancers of different phenotypes. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2013) 0.90
Nanoformulation of natural products for prevention and therapy of prostate cancer. Cancer Lett (2012) 0.90
Intravaginal Zinc Oxide Tetrapod Nanoparticles as Novel Immunoprotective Agents against Genital Herpes. J Immunol (2016) 0.90
Atherosclerotic plaque targeting mechanism of long-circulating nanoparticles established by multimodal imaging. ACS Nano (2015) 0.90
Improving chemoradiotherapy with nanoparticle therapeutics. Transl Cancer Res (2013) 0.89
Nanomedical engineering: shaping future nanomedicines. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2014) 0.89
Challenges and opportunities in the advancement of nanomedicines. J Control Release (2012) 0.89
Cell-penetrating, guanidinium-rich molecular transporters for overcoming efflux-mediated multidrug resistance. Mol Pharm (2014) 0.89
Monocytes and macrophages as nanomedicinal targets for improved diagnosis and treatment of disease. Expert Rev Mol Diagn (2013) 0.88
Biomaterials and emerging anticancer therapeutics: engineering the microenvironment. Nat Rev Cancer (2015) 0.88
Gold nanoshelled liquid perfluorocarbon magnetic nanocapsules: a nanotheranostic platform for bimodal ultrasound/magnetic resonance imaging guided photothermal tumor ablation. Theranostics (2013) 0.87
Nanomedicine in the Management of Microbial Infection - Overview and Perspectives. Nano Today (2014) 0.87
Replication-dependent irreversible topoisomerase 1 poisoning is responsible for FdUMP[10] anti-leukemic activity. Exp Hematol (2012) 0.87
Nanodrugs: pharmacokinetics and safety. Int J Nanomedicine (2014) 0.87
Targeted PRINT Hydrogels: The Role of Nanoparticle Size and Ligand Density on Cell Association, Biodistribution, and Tumor Accumulation. Nano Lett (2015) 0.86
Diamond nanogel-embedded contact lenses mediate lysozyme-dependent therapeutic release. ACS Nano (2014) 0.86
Nanoparticles containing insoluble drug for cancer therapy. Biotechnol Adv (2013) 0.86
Nanoparticles with photoinduced precipitation for the extraction of pollutants from water and soil. Nat Commun (2015) 0.86
Poly(2-oxazoline) based micelles with high capacity for 3rd generation taxoids: preparation, in vitro and in vivo evaluation. J Control Release (2015) 0.86
Nanotechnology: Future of Oncotherapy. Clin Cancer Res (2015) 0.86
Nanodiamonds: The intersection of nanotechnology, drug development, and personalized medicine. Sci Adv (2015) 0.85
Stimuli-responsive nanoparticles for targeting the tumor microenvironment. J Control Release (2015) 0.85
Biotargeted nanomedicines for cancer: six tenets before you begin. Nanomedicine (Lond) (2013) 0.85
Real-time, near-infrared fluorescence imaging with an optimized dye/light source/camera combination for surgical guidance of prostate cancer. Clin Cancer Res (2014) 0.85
Update on current and potential nanoparticle cancer therapies. Curr Opin Oncol (2013) 0.85
Curcumin nanomedicine: a road to cancer therapeutics. Curr Pharm Des (2013) 0.85
Polymeric nucleic acid vehicles exploit active interorganelle trafficking mechanisms. ACS Nano (2012) 0.85
Noninvasive Imaging of Nanomedicines and Nanotheranostics: Principles, Progress, and Prospects. Chem Rev (2015) 0.85
Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer. Proc Natl Acad Sci U S A (2016) 0.85
The effect of hyperbranched polyglycerol coatings on drug delivery using degradable polymer nanoparticles. Biomaterials (2014) 0.84
Hybrid lipid-polymer nanoparticles for sustained siRNA delivery and gene silencing. Nanomedicine (2014) 0.84
Nanotechnology: emerging tools for biology and medicine. Genes Dev (2013) 0.84
Mechanisms and implications of dual-acting methotrexate in folate-targeted nanotherapeutic delivery. Int J Mol Sci (2015) 0.84
Nanoparticles containing a liver X receptor agonist inhibit inflammation and atherosclerosis. Adv Healthc Mater (2014) 0.84
Cell membrane-camouflaged nanoparticles for drug delivery. J Control Release (2015) 0.83
Targeted Nitric Oxide Delivery by Supramolecular Nanofibers for the Prevention of Restenosis After Arterial Injury. Antioxid Redox Signal (2016) 0.83
Antitumor activity of docetaxel-loaded polymeric nanoparticles fabricated by Shirasu porous glass membrane-emulsification technique. Int J Nanomedicine (2013) 0.83
Heterobivalent agents targeting PSMA and integrin-αvβ3. Bioconjug Chem (2014) 0.82
Theranostic nanoparticles carrying doxorubicin attenuate targeting ligand specific antibody responses following systemic delivery. Theranostics (2015) 0.82
Novel polymeric nanoparticles for intracellular delivery of peptide Cargos: antitumor efficacy of the BCL-2 conversion peptide NuBCP-9. Cancer Res (2014) 0.82
Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol (2007) 17.80
Gene expression correlates of clinical prostate cancer behavior. Cancer Cell (2002) 16.27
The genomic complexity of primary human prostate cancer. Nature (2011) 14.06
Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov (2009) 12.46
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93
Engineering vascularized skeletal muscle tissue. Nat Biotechnol (2005) 7.73
Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm (2008) 7.67
Autoantibody signatures in prostate cancer. N Engl J Med (2005) 7.56
Punctuated evolution of prostate cancer genomes. Cell (2013) 7.23
Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell (2009) 7.09
Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol (2003) 6.93
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A (2006) 6.90
Impact of nanotechnology on drug delivery. ACS Nano (2009) 6.87
A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol (2008) 6.81
Microscale technologies for tissue engineering and biology. Proc Natl Acad Sci U S A (2006) 6.66
Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA (2010) 5.78
Nanoliter-scale synthesis of arrayed biomaterials and application to human embryonic stem cells. Nat Biotechnol (2004) 5.51
Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol (2007) 5.12
Transdermal drug delivery. Nat Biotechnol (2008) 5.11
Adipose tissue mass can be regulated through the vasculature. Proc Natl Acad Sci U S A (2002) 4.77
Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science (2008) 4.71
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci U S A (2008) 4.57
Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol (2007) 4.56
Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res (2004) 4.56
Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol (2005) 4.55
Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol (2008) 4.46
A tough biodegradable elastomer. Nat Biotechnol (2002) 4.35
Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci U S A (2010) 4.25
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 4.24
Functional assembly of engineered myocardium by electrical stimulation of cardiac myocytes cultured on scaffolds. Proc Natl Acad Sci U S A (2004) 4.13
Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials (2006) 4.09
Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis. J Gene Med (2005) 4.04
Accordion-like honeycombs for tissue engineering of cardiac anisotropy. Nat Mater (2008) 4.00
A reversibly switching surface. Science (2003) 3.97
Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat Biotechnol (2011) 3.95
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol (2012) 3.92
Small-scale systems for in vivo drug delivery. Nat Biotechnol (2003) 3.90
Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab (2002) 3.85
Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci U S A (2008) 3.80
Nanoparticle delivery of cancer drugs. Annu Rev Med (2011) 3.75
EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science (2012) 3.74
Endothelial cells derived from human embryonic stem cells. Proc Natl Acad Sci U S A (2002) 3.66
Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol (2007) 3.65
Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci U S A (2008) 3.62
First-in-human testing of a wirelessly controlled drug delivery microchip. Sci Transl Med (2012) 3.56
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA (2008) 3.55
Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst (2008) 3.55
Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials. Lancet Oncol (2011) 3.48
Controlled degradation and mechanical behavior of photopolymerized hyaluronic acid networks. Biomacromolecules (2005) 3.44
Current status and future potential of transdermal drug delivery. Nat Rev Drug Discov (2004) 3.41
Oncomodulin is a macrophage-derived signal for axon regeneration in retinal ganglion cells. Nat Neurosci (2006) 3.35
Functional recovery following traumatic spinal cord injury mediated by a unique polymer scaffold seeded with neural stem cells. Proc Natl Acad Sci U S A (2002) 3.35
Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev (2012) 3.34
Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. Proc Natl Acad Sci U S A (2003) 3.34
Treating metastatic cancer with nanotechnology. Nat Rev Cancer (2011) 3.30
Hyaluronic acid hydrogel for controlled self-renewal and differentiation of human embryonic stem cells. Proc Natl Acad Sci U S A (2007) 3.19
Active surveillance for early-stage prostate cancer: review of the current literature. Cancer (2008) 3.18
Outbreak of adverse reactions associated with contaminated heparin. N Engl J Med (2008) 3.16
Nanotechnological strategies for engineering complex tissues. Nat Nanotechnol (2010) 3.15
Combinatorial development of biomaterials for clonal growth of human pluripotent stem cells. Nat Mater (2010) 3.11
Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery. Nat Nanotechnol (2012) 3.09
Engineering substrate topography at the micro- and nanoscale to control cell function. Angew Chem Int Ed Engl (2009) 3.09
Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res (2013) 2.98
Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis. Ann Intern Med (2013) 2.96
Microengineered hydrogels for tissue engineering. Biomaterials (2007) 2.87
Differentiation of human embryonic stem cells on three-dimensional polymer scaffolds. Proc Natl Acad Sci U S A (2003) 2.86
Semi-automated synthesis and screening of a large library of degradable cationic polymers for gene delivery. Angew Chem Int Ed Engl (2003) 2.83
89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med (2010) 2.82
The inflammatory responses to silk films in vitro and in vivo. Biomaterials (2005) 2.79
Biodegradable, elastic shape-memory polymers for potential biomedical applications. Science (2002) 2.79
Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov (2014) 2.79
Meta-analysis of the relationship between dose and benefit in phase I targeted agent trials. J Natl Cancer Inst (2012) 2.78
Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discov (2012) 2.76
Self-assembled lipid--polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano (2008) 2.76
Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res (2011) 2.69
Nanomedicine: developing smarter therapeutic and diagnostic modalities. Adv Drug Deliv Rev (2006) 2.69
Multi-pulse drug delivery from a resorbable polymeric microchip device. Nat Mater (2003) 2.65
Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol (2004) 2.65
A combinatorial polymer library approach yields insight into nonviral gene delivery. Acc Chem Res (2008) 2.63
A biodegradable and biocompatible gecko-inspired tissue adhesive. Proc Natl Acad Sci U S A (2008) 2.58
Macroporous nanowire nanoelectronic scaffolds for synthetic tissues. Nat Mater (2012) 2.57
Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody. Lab Chip (2009) 2.56
Evaluation of the 8q24 prostate cancer risk locus and MYC expression. Cancer Res (2009) 2.54
Light-induced shape-memory polymers. Nature (2005) 2.52
Risk of cardiovascular disease by hysterectomy status, with and without oophorectomy: the Women's Health Initiative Observational Study. Circulation (2005) 2.49
Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study. Lancet Oncol (2012) 2.44
Medium perfusion enables engineering of compact and contractile cardiac tissue. Am J Physiol Heart Circ Physiol (2003) 2.42
Prostate cancer, version 2.2014. J Natl Compr Canc Netw (2014) 2.40
Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. Nano Lett (2007) 2.40